Altheia: Proliferating PD-L1

How Altheia is boosting PD-L1 expression to treat autoimmune diseases

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis.

Altheia was founded by tech transfer company AurorA-TT in 2017 with rights to IP from Boston Children’s Hospital covering PD-L1-expressing hematopoietic stem cells (HSCs).


Read the full 594 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers